NCT03684863View on ClinicalTrials.gov

Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2025

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

Capecitabine

observation

All Listed Sponsors

lead

Shandong Cancer Hospital and Institute

OTHER